Shots: Dicerna to receive $200M up front and up to $1.47B development, regulatory and commercial milestones and royalties based on the sales of DCR-HBVS. Roche to get WW license to develop & commercialize DCR-HBVS utilizing Dicerna’s GalXC RNAi platform technology Dicerna holds an option to co-fund global development of DCR-HBVS, which if exercised, Dicerna will […]Read More
Shots: The companies enter into a global commercialization agreement for new Prostate-Specific Membrane Antigen (PSMA) PET/CT imaging agent. GE Healthcare to take care of all pre-approval commercial preparations plus all subsequent commercial and distribution activities. Theragnostics to lead the development of the tracer, GalliProst (Gallium-68 (68Ga) diagnostic tracer) benefiting treatments for Prostate Cancer The companies […]Read More
Shots: AstraZeneca to receive upfront, $243M on completion of the agreement with ~33M as a commercial milestone in 2021 and 2022. Cheplapharm to get global commercial rights for Losec & associated brands (Acimax, Antra, Mepral, Mopral, Omepral and Zoltum) excluding the US, China, Japan & Mexico The agreement allows AstraZeneca to focus on its three […]Read More
Shots: Sandoz to get WW rights to distribute & commercialize proposed biosimilar natalizumab in all markets following its approval. Polpharma Biologics will be responsible for development, manufacturing and supply of proposed biosimilar natalizumab The focus of the agreement is to expand Novartis/Sandoz’s portfolio across small molecules, complex generics, biosimilars, and innovator therapies with the addition […]Read More
Shots: Novartis to receive $20M (€17.9M) up front, regulatory and commercial milestones plus royalties on sales. Pharming to get exclusive rights to develop and commercialize Novartis’ CDZ173 (leniolisib). Additionally, Pharming will work with Novartis for enrolling patients in ongoing trials Novartis has accomplished all the preclinical and clinical activities regarding product and will continue […]Read More
Shots: Regenxbio and Neurimmune enter into a collaboration to develop vectorized Ab by combining antibodies identified using Neurimmune’s reverse translational medicine platform with Regenxbio’s NAV technology platform for chronic neuro-degenerative diseases including tauopathies The companies will jointly develop & commercialize AVV gene therapies with equal development cost-sharing with an initial focus on tauopathies. Following initial […]Read More
Shots: Alvotech will take care of development and supply of the product while Cipla Gulf, subsidiary of Cipla will be responsible for Alvotech’s AVT02 registration and commercialization The agreement will allow Alvotech to have access for Cipla’s strong commercial network in selected emerging markets enabling patients with high-quality biosimilars Alvotech’s AVT02 is a mAb and […]Read More
Shots: Photocure to receive $5M upfront within 6mos. after signing the agreement and $14M on the approval of the second indication in the US, China & EU with royalties on sales. Photocure will also receive $18M & $36M as a regulatory & clinical milestone in China & the US and EU respectively The companies collaborated […]Read More
Shots: Daiichi to return rights for four diagnostic imaging agents to GE Healthcare Omnipaque, Omniscan, including Visipaque, Sonazoid and the transfer of marketing authorization rights is expected to be complete in Mar’2020 GE Healthcare will be responsible for commercialization & regulatory activities for all four imaging agents. Daiichi will hold the rights to distribute the […]Read More
Shots: BeiGene to receive $150M and regains WW rights for tislelizumab with their mutual termination of WW development & commercialization agreement with Celgene, following the pending acquisition of Celgene by BMS In Jul’17, BeiGene granted exclusive WW rights (Ex- Asia) of tislelizumab for solid tumor and retained global rights for hematology & solid tumor in […]Read More
Copyright ©2020 PharmaShots | Powered by Octavus Consulting
